SB 509

Drug Profile

SB 509

Alternative Names: hVEGF-A; SB-509; VEGF activator zinc finger protein

Latest Information Update: 12 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sangamo BioSciences
  • Class Gene therapies; Neuroprotectants; Zinc finger DNA binding proteins
  • Mechanism of Action Gene transference; Genetic transcription stimulants; Vascular endothelial growth factor A expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Amyotrophic lateral sclerosis; Brain injuries; Diabetic neuropathies; Spinal cord injuries; Stroke

Most Recent Events

  • 06 Jan 2017 Sangamo Biosciences is now called Sangamo Therapeutics
  • 03 Oct 2011 Discontinued - Phase-II for Amyotrophic lateral sclerosis in USA (IM)
  • 03 Oct 2011 Discontinued - Phase-II for Diabetic neuropathies in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top